Ncardia, a leading human induced pluripotent stem cell (hiPSC) technology company, today announced the launch of Ncyte® Heart ...

In cell culture, human cardiomyocytes significantly proliferate ... increased chance of ventricular arrhythmias and clinical end-stage heart failure. The current study advances a 2021 study ...

Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem ...

Advances in our understanding of the molecular basis of ventricular dysfunction and ... these cells do not differentiate into mature cardiomyocytes. Skeletal-myoblast-based therapy has also ...

In particular, we are interested in two cell types: cardiomyocytes, i.e. heart muscle cells ... and fibrosis (stiffening) of the left ventricular wall. We develop, screen and characterise new ...

In cell culture, human cardiomyocytes significantly proliferate ... progressive loss of pumping ability, increased chance of ventricular arrhythmias and clinical end-stage heart failure. The current ...